CLINUVEL Kommuniqué V
CLINUVELs fünftes Nachrichtenkommuniqué für 2021. Bespricht EPP, klinisches Programm, IR-Update und mehr.
Read More
CLINUVEL Communiqué V
CLINUVEL’s fifth News Communiqué for 2021. Discusses EPP, clinical program, IR update...
Read More
CLINUVEL’S GROWTH AND EXPANSION - Jefferies London Healthcare Conference
CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the 2021 Jefferies...
Read More
Results of Annual General Meeting 2021
In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations...
Read More
CEO's Address - 2021 Annual General Meeting
2021 CLINUVEL Annual General Meeting address from CEO, Dr Philippe Wolgen
Read More
CLINUVEL Expands Pharmaceutical Portfolio
Melanocortin drug NEURACTHEL® (ACTH) added for neurological, endocrinological and degenerative disorders
Read More
Strategic Update III
CLINUVEL PHARMACEUTICALS LTD today released its third Strategic Update.
Read More
CLINUVEL Adds ACTH to Portfolio
Melbourne, Australia, 08 November 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
CLINUVEL Investor Webinar Released
CLINUVEL PHARMACEUTICALS LTD today announced an Investor Webinar shall be held on...
Read More
First Patient Treated in CLINUVEL DNA Repair Study
Melbourne, Australia, 22 October 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
CLINUVEL Investor webinar
CLINUVEL PHARMACEUTICALS LTD today announced an Investor Webinar shall be held on...
Read More
Appendix 4G & Corporate Governance Statement
Melbourne, Australia, 08 October 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More